Found 34 clinical trials
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-
Alteplase for Acute Ischemic Stroke Within 4.5 Hours
- 0 views
- 05 Aug, 2021
- 61 locations
Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion
allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase before undergoing intra-arterial clot retrieval. The trial is
- 0 views
- 01 Jul, 2021
- 7 locations
REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT)
Stroke is one of the leading causes of death worldwide and the main cause of incapacity. Currently, the only therapies for acute ischemic stroke (AIS) patients are the administration of recombinant tissue plasminogen activator (rt-PA) and/or endovascular treatment. Unfortunately, many patients cannot benefit from these therapies due to contraindications or …
- 1 views
- 23 Jan, 2021
- 2 locations
Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study (respectively Part 1 and 2). The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the …
- 0 views
- 13 Oct, 2021
- 1 location
Recombinant Non-immunogenic Staphylokinase VS Alteplase for Massive PE a Randomized Non-inferiority Trial
Alteplase in patients with massive pulmonary embolism
- 0 views
- 27 Jan, 2021
- 7 locations
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV
- 1 views
- 26 Jun, 2021
- 1 location
A Phase III Randomized Blind Double Dummy Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours improve visual deficit due to acute CRAO with a good safety profile.
- 22 views
- 11 Nov, 2021
- 28 locations
Fingolimod in Endovascular Treatment of Ischemic Stroke
outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This study aim to determine
- 0 views
- 26 Jan, 2021
- 1 location
Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK)
reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. This study intends to explore the proportion of sufficient
- 0 views
- 12 Aug, 2021
- 1 location
Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke
The clinical study with UMC119-06 is designed to investigate the safety in patients with acute ischemic stroke ("AIS"). This will be a dose escalation, open-label, single-center study in adult with acute ischemic stroke. UMC119-06 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product which is intended for …
- 1 views
- 03 May, 2021
- 1 location